A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2004
12/28/2004	CA2331297C Hygromycin a derivatives
12/28/2004	CA2226039C Pyridylfuran and pyridylthiophene compounds
12/28/2004	CA2105923C 7-isoindolinyl-quinolone derivatives and 7-isoindolinyl-naphthyridone derivatives
12/26/2004	CA2458893A1 Treatment of chronic human viral hepatitis
12/23/2004	WO2004111082A2 Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
12/23/2004	WO2004111071A1 5'-aminocarbonyl-phosphonates d4t inhibitors for reproducing human immunodeficiency virus
12/23/2004	WO2004111064A1 Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
12/23/2004	WO2004111037A1 Cyclic tertiary amine compound
12/23/2004	WO2004111027A1 The isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as the effective constituents
12/23/2004	WO2004110999A1 Tetrahydrocarbazole derivatives and their pharmaceutical use
12/23/2004	WO2004110979A2 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
12/23/2004	WO2004110486A1 Functionally reconstituted viral membranes containing adjuvant
12/23/2004	WO2004110485A1 Materials and methods for improved vaccination
12/23/2004	WO2004110484A1 Method for producing a live tissue-cultural vaccine against influenza virus
12/23/2004	WO2004110482A1 Improved vaccines
12/23/2004	WO2004110481A2 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
12/23/2004	WO2004110480A2 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines
12/23/2004	WO2004110464A1 Use of a compound for inhibiting viral particles
12/23/2004	WO2004110454A1 COMPOSITION FOR TREATMENT FOR OR PREVENTION OF DISEASE NECESSITATING ADMINISTRATION OF ADENOSINE A2a RECEPTOR AGONIST
12/23/2004	WO2004110442A1 Pyridine n-oxides as antiviral agents
12/23/2004	WO2004110441A1 Pharmaceutical formulations comprising amoxicillin and clavulanate
12/23/2004	WO2004110392A2 Compositions and methods for treating coronavirus infection and sars
12/23/2004	WO2004093904A3 Modified live vaccines comprising bhv-1(ibr) and/or bvdv pregnant and nursing cattles
12/23/2004	WO2004087759A3 Method and compositions for conversion of antibody activity
12/23/2004	WO2004083251A3 Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
12/23/2004	WO2004082586A3 Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
12/23/2004	WO2004074270A3 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
12/23/2004	WO2004073599A3 Inhibitors of hepatitis c virus, compositions and treatments using the same
12/23/2004	WO2004064715A3 Polyhydroxylated pyrrolizidine
12/23/2004	WO2004042002A3 Compounds for modulating rna interference
12/23/2004	WO2003101995A8 Camptothecins with a modified lactone ring
12/23/2004	US20040260095 human immunodeficiency virus (HIV) protease inhibitors; AIDS; prophylaxis
12/23/2004	US20040260094 such as 8-amino-4-benzylamino-quinoline-3-carboxylic acid ethyl ester; for treatment of Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS, stroke, ischemia, traumatic brain injury, spinal cord injury or osteoarthritis
12/23/2004	US20040260084 Having an acceptable side chain radical bonded to the 3 position of the cephalosporin ring by an aminomethylthio- or an oxymethylthio- group, e.g., (6R,7R)-(3-methoxymethylthio-8-oxo-7(-2-phenylacetamino)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene)-2-carboxylic acid
12/23/2004	US20040259973 Anti-bacterial composite particles and anti-bacterial resin composition
12/23/2004	US20040259930 Linear basic compounds having nk-2 antagonist activity and formulations thereof
12/23/2004	US20040259928 Enzyme inhibitors for antidiabetic agents, antitumor disorders, treatment of skin disorters, anticancer agents and cognitive activators for Alzheimers disease treatment
12/23/2004	US20040259911 Quinoline derivatives process of synthesis and medicaments containing these derivatives
12/23/2004	US20040259907 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents
12/23/2004	US20040259876 Bicyclic compound, production and use thereof
12/23/2004	US20040259864 Substituted pyrimidinone derivatives as ligands of integrin receptors
12/23/2004	US20040259863 Type 4 phosphodiesterase inhibitors and uses thereof
12/23/2004	US20040259840 Using phosphoglycerides, lipid having sphingosine base, glycerides and sterol; wound healing agents; atherosclerosis
12/23/2004	US20040259835 Stabilized brivudine topical formulations
12/23/2004	US20040259833 DNA methyl transferase inhibitors
12/23/2004	US20040259825 Gene expression vectors; intensifier dor sequence determiantion; induce immunology response; viricides
12/23/2004	US20040259822 Antibody which recognizes epitope containing nucleic acid coupled to active protein; hybridomas
12/23/2004	US20040259821 In nonaqueous solvent; therapy for blood disorders; anticancer agents
12/23/2004	US20040259820 Kit for delivering decitabine in vivo
12/23/2004	US20040259810 Porphyrin derivatives for photodynamic therapy
12/23/2004	US20040259797 peptide mixture; induce immunology response; gag protein; vaccines
12/23/2004	US20040259795 Reducing sepsis; binding polypeptide to monoclonal antibody ; intensify gene expression; wound healing agents
12/23/2004	US20040259773 Viricide peptide; nucleic acids encoding cyclic peptide
12/23/2004	US20040259767 Antiproliferative agents; therapy for human progessive leukoencephalophy ; suppression of dna viruses; anticancer agents
12/23/2004	US20040259248 RNA interference mediating small RNA molecules
12/23/2004	US20040259247 short interfering RNAs for use treating diseases, in protein separation or purification, in drug screening; cell with target gene-specific knockout phenotype; double stranded RNA; RNA fragments are the sequence-specific mediators of RNAi (RNA interference)
12/23/2004	US20040259201 Recombinant surfactant protein D compositions and methods of use thereof
12/23/2004	US20040259150 Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
12/23/2004	US20040259110 Gene PRV-1 and its use
12/23/2004	US20040259103 NKR (Natural Killer Receptor); rapidly analyze physiological and pathological situations linked to these repertoires; use in diagnosise/prognosis of patients for transplant acceptance, resistance to infections and disease, and in drug screening for autoimmune diseases, antitumor agents, and antibiotics
12/23/2004	US20040258739 Plaster for the treatment of dysfunctions and disorders of nails
12/23/2004	US20040258720 Cosmetics; skin disorders, antiinflammatory agents
12/23/2004	US20040258709 Hepatitis B virus polypeptides
12/23/2004	US20040258708 Cytotoxic T-cell epitopes of papillomavirus L1 protein and their use in diagnostics and therapy
12/23/2004	US20040258707 Nucleotide sequences encoding the structural proteins (causative agent) which consists of a basic capsid protein, three envelope proteins designated as E1, E2 and E3, and a 6K protein; stable DNA vaccines and vector vaccines of live attenuated modified bacteria or virus; kits for medical diagnosis
12/23/2004	US20040258694 Hepatitis C receptor protein CD81
12/23/2004	US20040258675 Novel mutated form of arginine deiminase
12/23/2004	US20040258664 Inducing phagocytosis; treating cow mastitis without leaving drugs in milk or producing drug-resistant bacterial strains; fish furunculosis
12/23/2004	US20040258663 Maintaining sustained levels and optimizing intranasal dosing schedules without causing intolerable side effects
12/23/2004	US20040258656 Identified via SELEX method; phosphate-containing ligand is conjugated to polyoxyethylene glycol; transforming growth factor (TGF); pharmacokinetics
12/23/2004	CA2727748A1 Inosine derivatives and production methods therefor
12/23/2004	CA2529102A1 Pharmaceutical formulations comprising amoxicillin and clavulanate
12/23/2004	CA2528929A1 Cyclic tertiary amine compound
12/23/2004	CA2528321A1 Tetrahydrocarbazole derivatives and their pharmaceutical use
12/23/2004	CA2528240A1 Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
12/23/2004	CA2527977A1 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
12/23/2004	CA2527735A1 Functionally reconstituted viral membranes containing adjuvant
12/23/2004	CA2527586A1 Pyridine n-oxides as antiviral agents
12/23/2004	CA2526416A1 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines
12/23/2004	CA2520148A1 Compositions and methods for treating coronavirus infection and sars
12/23/2004	CA2515369A1 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
12/22/2004	EP1489185A1 Methods and compositions for use in splicesome mediated rna trans-splicing
12/22/2004	EP1489165A1 Recombinant fowlpox vaccine for protection against marek's disease
12/22/2004	EP1489101A1 Novel branched sialo-sugar molecules and antiviral agents using the same
12/22/2004	EP1489099A2 Antibodies that bind the CD40CR receptor
12/22/2004	EP1489092A1 Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
12/22/2004	EP1489088A1 Novel alpha-amino-n-(diaminophosphinyl)lactam derivative
12/22/2004	EP1489084A1 Broad-spectrum cephem compounds
12/22/2004	EP1488810A1 Percutaneous absorption promoters and compositions for treating athlete's foot
12/22/2004	EP1488805A2 CD28 pathway immunoregulation
12/22/2004	EP1488699A1 Synergistic microbicidal combinations
12/22/2004	EP1487992A2 Central airway administration for systemic delivery of therapeutics
12/22/2004	EP1487968A1 Methods of inducing differentiation of stem cells into a specific cell lineage
12/22/2004	EP1487879A2 Bispecific antibody point mutations for enhancing rate of clearance
12/22/2004	EP1487870A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
12/22/2004	EP1487863A2 Process for purifying glycopeptide phospohonate derivatives
12/22/2004	EP1487842A1 An optically acitve pyridine derivative and a medicament containing the same
12/22/2004	EP1487834A1 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
12/22/2004	EP1487827A1 Anti-inflammatory morpholin-acetamide derivatives
12/22/2004	EP1487817A1 Piperidine derivatives useful as modulators of chemokine receptor activity

1 ... 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 ... 1798